RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer
Shaohui Jiang, Weijie He, Zhimin Li, Haodong He, Yuehua Li, Meiling Wen, Hongbo Zhu, Pengfei Luo · 2025
Read RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer by Shaohui Jiang, Weijie He, Zhimin Li, Haodong He, Yuehua Li, Meiling Wen, Hongbo Zhu, Pengfei Luo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717349.txt.
Description
Shaohui Jiang and seven co-authors investigate a long non-coding RNA that seems to restrain breast cancer and shape its response to immune therapy, in this 2025 study. The molecule, RERE-AS1, does not code for a protein; it regulates. Its role in breast cancer was essentially unknown.
Mining patient data, the team found the RNA sharply reduced in breast tumors, with higher levels tracking better outcomes. In two breast cancer cell lines, restoring it slowed growth, movement, and invasion, pushed cells toward death, and stalled their division cycle. Co-cultures showed it also changed how immune cells attacked the tumor. A mouse experiment then tested tumor growth and response to anti-PD-1 immunotherapy with the RNA present. Molecules like this are doubly attractive: a marker that forecasts a patient's course, and possibly a lever that makes immunotherapy work where it currently fails.
Catalog record
| CREATOR | Shaohui Jiang, Weijie He, Zhimin Li, Haodong He, Yuehua Li, Meiling Wen, Hongbo Zhu, Pengfei Luo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |